Legend Biotech Corp (LEGN) Stock AnalysisLEGNLegend Biotech Corp

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Legend Biotech Corp (LEGN) is currently trading at $18.48, which is significantly below its 200-day simple moving average of $22.236, suggesting it may not be a strong buy at this moment. The RSI is at 45.875, indicating it is neither overbought nor oversold. While the company reported a profit of $33.2 million in Q2 2026, a notable improvement from a loss of $125.4 million in the same quarter last year, the overall trend shows a year-to-date decline of 14.09% and a one-year decline of 43.85%. The recent FDA IND clearance for LB2501 is a positive catalyst, but the stock's performance and analyst downgrades suggest caution. The main risk is the significant decline in net income, which was -$54.3 million in Q1 2026, highlighting ongoing financial challenges.